Meeting
2020 ASCO Virtual Scientific Program
Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).
Authors
Taofeek Kunle Owonikoko
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA
Taofeek Kunle Owonikoko , Hossein Borghaei , Stéphane Champiat , Luis G. Paz-Ares , Ramaswamy Govindan , Michael J. Boyer , Melissa Lynne Johnson , Hibiki Udagawa , Horst-Dieter Hummel , Ravi Salgia , Fiona Helen Blackhall , Rene J. Boosman , Wei-Chu Victoria Lai , Afshin Dowlati , Everett E. Vokes , Christine L. Hann , Anne C. Chiang , Marichu Endraca , Neelesh Soman , Marie-Anne Damiette Smit
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03319940
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS9080)
DOI
10.1200/JCO.2020.38.15_suppl.TPS9080
Abstract #
TPS9080
Poster Bd #
273
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 2 study of tarlatamab, a DLL3-targeting, half life–extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC).
First Author: Suresh S. Ramalingam
Poster
2021 ASCO Annual Meeting
Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
First Author: Rahul Raj Aggarwal
Poster
2019 ASCO Annual Meeting
Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).
First Author: Marie-Anne Damiette Smit
Poster
2023 ASCO Annual Meeting
Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).
First Author: Luis G. Paz-Ares